22501-77-5

Usage

Uses

Used in Pharmaceutical Industry:
4-(5-METHYL-BENZOOXAZOL-2-YL)-PHENYLAMINE serves as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs and medicinal compounds. Its unique structure allows for versatile chemical modifications, facilitating the creation of diverse pharmaceutical agents.
Used in Dye Industry:
In the dye industry, 4-(5-METHYL-BENZOOXAZOL-2-YL)-PHENYLAMINE is utilized as an intermediate for the production of various dyes. Its chemical properties enable the synthesis of dyes with specific color characteristics and stability, catering to the needs of different applications.
Used in Organic Compounds Synthesis:
4-(5-METHYL-BENZOOXAZOL-2-YL)-PHENYLAMINE is employed as an intermediate in the synthesis of other organic compounds, broadening its applications across various chemical and industrial processes. Its structural features make it a valuable component in the development of specialty chemicals and materials.

InChI:InChI=1/C14H12N2O/c1-9-2-7-13-12(8-9)16-14(17-13)10-3-5-11(15)6-4-10/h2-8H,15H2,1H3

Upstream product

• 150-13-0 4-amino-benzoic acid 
• 95-84-1 3-amino-4-hydroxytoluene 
• 119-33-5 4-methyl-2-nitrophenol 
• 893-17-4 5-methyl-2-(4-nitrophenyl)-1,3-benzothiazole 
• 122-04-3 4-nitro-benzoyl chloride 

Downstream Products

• 1033803-07-4 2-bromo-4-(5-methylbenzoxazol-2-yl)phenylamine 

Relevant academic research and scientific papers

Synthesis of some new benzoxazole derivatives and investigation of their anticancer activities

Phortress is an anticancer prodrug, which has active metabolite (5F-203) being potent agonist of the aryl hydrocarbon receptor (AhR). The 5F-203 switches on cytochrome P450 CYP1A1 gene expression and thus exhibits anticancer activity. In this study, it is

Preparation method 2 -benzooxazole compound (by machine translation)

The invention belongs to the technical field of organic compound synthesis, and particularly relates to a preparation method of 2 -benzene benzotriazole compound. The 2 - aminophenol compound is added into 1 organic solvent, then first aminophenol compounds are added, and the condensation intermediate obtained in the formula (2 -) is added to an organic solvent, and under the action of the catalyst, the reflux reaction is heated, cooled and filtered or concentrated to obtain 2 2 -benzooxazole 1 compound 2nd. 2 -benzene benzotriazole compounds are high in quality, good in stability, high in raw material utilization rate and easy to operate, and is a method suitable for large-scale industrial production. (by machine translation)

Virtual screening identification and chemical optimization of substituted 2-arylbenzimidazoles as new non-zinc-binding MMP-2 inhibitors

Matrix metalloproteinases (MMPs) are a large family of zinc-dependent endoproteases known to exert multiple regulatory roles in tumor progression and invasiveness. This encouraged over the years the approach of MMP, and particularly MMP-2, targeting for anticancer treatment. Early generations of MMP inhibitors, based on aspecific zinc binding groups (ZBGs) assembled on (pseudo)peptide scaffolds, have been discontinued due to the clinical emergence of toxicity and further drawbacks, giving the way to inhibitors with alternative zinc-chelator moieties or not binding the catalytic zinc ion. In the present paper, we continue the search for new non-zinc binding MMP-2 inhibitors: exploiting previously identified compounds, a virtual screening (VS) campaign was carried out and led to the identification of a new class of ligands. The structure-activity relationship (SAR) of the benzimidazole scaffold was explored by synthesis of several analogues whose inhibition activity was tested with enzyme inhibition assays. By performing the molecular simplification approach, we disclosed different sets of single-digit micromolar inhibitors of MMP-2, with up to a ten-fold increase in inhibitory activity and ameliorated selectivity towards off-target MMP-8, compared to selected lead compound. Molecular dynamics calculations conducted on complexes of MMP-2 with docked privileged structures confirmed that analyzed inhibitors avoid targeting the zinc ion and dip inside the S1′ pocket. Present results provide a further enrichment of our insights for the design of novel MMP-2 selective inhibitors.

Preparation method of 2-phenylbenzoxazole compound

The invention relates to a preparation method of a 2-phenylbenzoxazole compound, comprising the following steps: (1) condensation reaction: a 2-amino phenol compound and a benzoyl chloride compound, which are used as raw materials, react in an organic solvent to obtain a condensation reaction solution; and (2) cyclization reaction: as a cyclization catalyst, acid is added into the condensation reaction solution to carry out a cyclization reaction at a certain temperature so as to obtain a cyclization reaction solution; after the reaction, an organic solvent is added for heating refluxing; andcooling filtration or liquid-separation condensation is finally carried out to obtain a 2-phenylbenzoxazole compound. The technology is simple; product post-treatment is simple; environmental pollution is less; the prepared 2-phenylbenzoxazole compound has high product quality and good stability; in addition to general use purpose, the prepared product also can be used for preparation of a high-end luminescent material; and the preparation method is a method suitable for industrial preparation.

BENZOXAZOLES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided the use of a compound of formula (I): wherein Y, W1 to W4, Z1 to Z4 and R have meanings given in the description, and pharmaceutically-acceptable salts thereof, for the manufacture of a medicament for the treatment of a disease in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS

The present invention is directed at substituted heteroaryl- and phenylsulfamoyl compounds, pharmaceutical compositions containing such compounds and the use of such compounds as peroxisome proliferator activator receptor (PPAR) agonists. PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans. The compounds are also useful for the treatment of negative energy balance (NEB) and associated diseases in ruminants.

Biological evaluation of hepatitis C virus helicase inhibitors

A small chemical library has been synthesized and assayed for inhibition of HCV helicase activity. This study provides the structure-activity relationship of the reported inhibitors, with emphasis placed on the aminophenylbenzimidazole moiety and the link